Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Debt Repayment

Cash used to repay borrowings during the period.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q2 FY2026 debt repayment of $2.25M (cash outflow) rose 8.0% year over year, ahead of the +2.7% change in trailing-twelve-month debt repayment. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +354.1% a year.

Context

  • Debt repayment amounted to 11.3% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Debt repayment grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.0% holds above the trailing-twelve-month pace of +2.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.25M+1.9% QoQ
Last fiscal yearDec 2025
-$8.43M+89.8% YoY
LTMJun 2026
-$8.75M+2.7% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.0%——
1 year+89.8%——
3-year CAGR+354.1%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(8.43M) USD
Year-over-year change
-89.8%

Debt Repayment vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's LTM Jun 2026 debt repayment of $8.75M is the 2nd largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +2.7% is the 2nd highest of 3, against a peer median of +122.7%.
  • Debt repayment amounts to 16.0% of revenue for RXRX, versus a peer median of 38.2%.
RXRX Competitors Peer median
Debt Repayment for RXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAZEMaze Therapeutics, Inc.LTM Mar 2026$38.52M +342.0%—192.6%
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$8.75M +2.7%+354.1%16.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$1.38M -96.5%—38.2%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding RXRX) $0+122.7%—38.2%

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(186.48M)(239.48M)(328.07M)(463.66M)(644.76M)
Depreciation & Amortization8.41M11.76M24.4M36.49M83.7M
Deferred Income Tax827K0000
Stock-Based Compensation14.84M27.91M53.5M81.69M111.22M
Change in Working Capital(306K)104.92M(44.26M)(38M)13.69M
Accounts Receivables114K(2K)(7.76M)(6.07M)32.94M
Inventory7.84M0000
Accounts Payables1.75M1.77M(987K)6.44M(2.62M)
Other Working Capital(10M)103.16M(35.51M)(38.37M)(16.64M)
Other Non-Cash Items4.1M11.37M6.64M24.31M64.34M
Operating Cash Flow(158.61M)(83.52M)(287.78M)(359.17M)(371.81M)
Capital Expenditures(39.8M)(37.36M)(11.96M)(13.7M)(6.47M)
Acquisitions (Net)231.95M01.84M277.1M0
Purchases of Investments(301.14M)000(3.81M)
Sales of Investments69.19M230.61M480K00
Other Investing Activities(231.95M)(300K)(597K)(3.35M)(6.6M)
Investing Cash Flow(271.74M)193.25M(10.23M)260.06M(16.87M)
Debt Repayment(12.8M)(90K)(766K)(4.44M)(8.43M)
Common Stock Issued462.9M143.71M128.09M300.42M532.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.44M10.72M12.81M8.14M(3M)
Financing Cash Flow458.54M154.35M140.13M304.12M521.53M
Effect of Forex Changes0(307K)188K(3.41M)18.04M
Net Change in Cash28.18M263.76M(157.69M)201.6M150.9M
Free Cash Flow(198.41M)(120.88M)(300.33M)(372.87M)(378.28M)

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.